522 Results

People

  1. De Angelis
    De Angelis
  2. Kris
    Kris
  3. Motzer
    Motzer
  4. Livingston
    Livingston
  5. Aghajanian
    Aghajanian
  6. Krown
    Krown
  7. Panageas
    Panageas
  8. Miller
    Miller
  9. Tyson
    Tyson
  10. Vickers
    Vickers

Groups

  1. Department of Medicine (289)
  2. Solid Tumor Oncology Division (180)
  3. Hematologic Malignancies, Division of (104)
  4. Center for Hematologic Malignancies (92)
  5. Survivorship Research (61)
  6. GSK Faculty (55)
  7. Tow Center for Developmental Oncology (TCDO) (51)
  8. Epidemiology and Biostatistics (49)
  9. Population Sciences Research Program (45)
  10. Genitourinary Oncology Service (41)
  1. "headache"
Formats
  1. Journal Article (491)
  2. Review (17)
  3. Research Letter (5)
  4. Conference Paper (3)
  5. Editorial (3)
  6. Book Whole (1)
  7. Guidelines (1)
  8. Miscellaneous (1)
Groups
  1. Department of Medicine (289)
  2. Solid Tumor Oncology Division (180)
  3. Hematologic Malignancies, Division of (104)
  4. Center for Hematologic Malignancies (92)
  5. Survivorship Research (61)
  6. GSK Faculty (55)

More Groups

People
  1. Lisa De Angelis (20)
  2. Mark Kris (20)
  3. Robert Motzer (19)
  4. Philip Livingston (13)
  5. Carol Aghajanian (12)
  6. Katherine Panageas (12)

More People

Years
  1. 2025 (15)
  2. 2024 (34)
  3. 2023 (30)
  4. 2022 (16)
  5. 2021 (18)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (37)
  2. Clinical Cancer Research (23)
  3. Lancet Oncology (20)
  4. Blood (18)
  5. New England Journal of Medicine (17)
  6. Cancer (16)

More Publications

Publishers
  1. Elsevier Inc. (68)
  2. Elsevier Science, Inc. (43)
  3. Springer (42)
  4. American Society of Clinical Oncology (37)
  5. Nature Publishing Group (32)
  6. Oxford University Press (29)

More Publishers

Results (522)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: The ANNOUNCE randomized clinical trial
    Journal Article

    Tap, W. D.; Wagner, A. J.; Schöffski, P.; Martin-Broto, J.; Krarup-Hansen, A.; Ganjoo, K. N.; Yen, C. C.; Abdul Razak, A. R.; Spira, A.; Kawai, A.; more...
    JAMA - Journal of the American Medical Association (2020)

    Fulltext@MSK | Save
  • Phase I study of trifluridine/tipiracil plus irinotecan and bevacizumab in advanced gastrointestinal tumors
    Journal Article

    Varghese, A. M.; Cardin, D. B.; Hersch, J.; Benson, A. B.; Hochster, H. S.; Makris, L.; Hamada, K.; Berlin, J. D.; Saltz, L. B.
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Acalabrutinib and its therapeutic potential in the treatment of chronic lymphocytic leukemia: A short review on emerging data
    Review

    Isaac, K.; Mato, A. R.
    Cancer Management and Research (2020)

    Fulltext@MSK | Save
  • Clinician vs patient reporting of baseline and postbaseline symptoms for adverse event assessment in cancer clinical trials
    Research Letter

    Atkinson, T. M.; Dueck, A. C.; Satele, D. V.; Thanarajasingam, G.; Lafky, J. M.; Sloan, J. A.; Basch, E.
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: Interim results from a multicentre, open-label, phase 1b study
    Journal Article

    Sequist, L. V.; Han, J. Y.; Ahn, M. J.; Cho, B. C.; Yu, H.; Kim, S. W.; Yang, J. C. H.; Lee, J. S.; Su, W. C.; Kowalski, D.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • TATTON: A multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
    Journal Article

    Oxnard, G. R.; Yang, J. C. H.; Yu, H.; Kim, S. W.; Saka, H.; Horn, L.; Goto, K.; Ohe, Y.; Mann, H.; Thress, K. S.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A phase 1b study of cetuximab and BYL719 (alpelisib) concurrent with intensity modulated radiation therapy in stage III-IVB head and neck squamous cell carcinoma
    Journal Article

    Dunn, L. A.; Riaz, N.; Fury, M. G.; McBride, S. M.; Michel, L.; Lee, N. Y.; Sherman, E. J.; Baxi, S. S.; Haque, S. S.; Katabi, N.; more...
    International Journal of Radiation Oncology, Biology, Physics (2020)

    Fulltext@MSK | Save
  • A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer
    Journal Article

    Moore, K. N.; Miller, A.; Bell-McGuinn, K. M.; Schilder, R. J.; Walker, J. L.; O'Cearbhaill, R. E.; Guntupalli, S. R.; Armstrong, D. K.; Hagemann, A. R.; Gray, H. J.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Academic Consortium for Integrative Medicine & Health commentary to CMS; RE: National coverage analysis (NCA) tracking sheet for acupuncture for chronic low back pain (CAG-00452N)
    Journal Article

    Nielsen, A.; Tick, H.; Mao, J. J.; Hecht, F.; and the Consortium Pain Task Force
    Global Advances In Health and Medicine (2019)

    Fulltext@MSK | Save
  • Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
    Journal Article

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Williams, D. A.; Shukla, N.; Kobos, R.; Forlenza, C. J.; Steinherz, P.; Prockop, S.; more...
    Blood (2019)

    Fulltext@MSK | Save